229 related articles for article (PubMed ID: 31022775)
1. Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.
McFarland DC; Jutagir DR; Rosenfeld B; Pirl W; Miller AH; Breitbart W; Nelson C
Psychooncology; 2019 Jul; 28(7):1461-1469. PubMed ID: 31022775
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
3. Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.
Jacobs JM; Traeger L; Eusebio J; Simon NM; Sequist LV; Greer JA; Temel JS; Pirl WF
J Psychosom Res; 2017 Aug; 99():28-33. PubMed ID: 28712427
[TBL] [Abstract][Full Text] [Related]
4. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C; Peng S; Li P; Ma L; Gan X
Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
[TBL] [Abstract][Full Text] [Related]
5. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
7. Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.
Pirl WF; Traeger L; Greer JA; Bemis H; Gallagher E; Lennes I; Sequist L; Heist R; Temel JS
Oncologist; 2011; 16(9):1299-306. PubMed ID: 21807767
[TBL] [Abstract][Full Text] [Related]
8. N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.
Han CL; Chen XR; Lan A; Hsu YL; Wu PS; Hung PF; Hung CL; Pan SH
Cancer Sci; 2021 May; 112(5):1911-1923. PubMed ID: 33706413
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
10. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
McFarland DC; Shaffer K; Breitbart W; Rosenfeld B; Miller AH
Cancer; 2019 Mar; 125(5):779-787. PubMed ID: 30521079
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
15. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Mittal S; Kamath A; Joseph AM; Rajala MS
Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer.
Xu S; Zhu J; Zhong D; Wang W; Wen Y; Zhang L; Jiang T
J Surg Res; 2023 Mar; 283():674-682. PubMed ID: 36459860
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
[TBL] [Abstract][Full Text] [Related]
19. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Huang KT; Chen HC; Chang YC; Lin MC
Medicine (Baltimore); 2015 Dec; 94(50):e2239. PubMed ID: 26683939
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
